Showing 4031-4040 of 8124 results for "".
Why I Prefer Zymar
https://crstoday.com/crst-issues/2005-feb/0205_f7_snyder-html/40874/The new fluoroquinolone has advantages that surgeons can depend on, its strength and prolonged efficacy.Preventing Endophthalmitis
https://crstoday.com/crst-issues/2005-feb/0205_f3_olson-html/40871/Are we moving forward or backward?How the Restor's apodized, refractive, diffractive optic works.
https://crstoday.com/crst-issues/2005-jun/crst0605_08-php/40786/Deciphering DiffractionTrachoma: Still A Major Cause of Preventable Blindness
https://crstoday.com/topics/refractive-surgery/crst1005_13-php-2/40737/Moving toward a world without blinding trachoma.Trachoma: Still A Major Cause of Preventable Blindness
https://crstoday.com/topics/refractive-surgery/crst1005_13-php/40692/Moving toward a world without blinding trachoma.Phacoemulsification of the High-Risk Lens
https://crstoday.com/crst-issues/2004-oct/1004_reviv-html/40479/Confronting the quadruple S: small pupil, super-dense lens, shallow chamber, and shaky zonules.Refractive Challenge
https://crstoday.com/crst-issues/2003-jan/crst0103_07-php/40444/LASIK Epithelial SlidersRefractive Challenge
https://crstoday.com/crst-issues/2002-jul/crst0702_08-php/40133/Salzmann's Nodular DegenerationThe Off-Label Use of Pharmaceuticals
https://crstoday.com/crst-issues/2002-nov/1102_201-html/40076/New uncharted indications may provide patient benefit in LASIK, but is there risk?The Economics of Innovation in Rare Eye Disease: Lessons from Epithelium-On Corneal Cross-Linking
https://crstoday.com/crst-supplements/the-economics-of-innovation-in-rare-eye-disease-lessons-from-epithelium-on-corneal-cross-linking/the-economics-of-innovation-in-rare-eye-disease-lessons-from-epithelium-on-corneal-cross-linking/54527/